Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials [REVIEW ARTICLES]

Conclusion Comprehensive analysis of phase II, single-agent arms revealed that, across malignancies, a personalized strategy was an independent predictor of better outcomes and fewer toxic deaths. In addition, nonpersonalized targeted therapies were associated with significantly poorer outcomes than cytotoxic agents, which in turn were worse than personalized targeted therapy.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Clinical Trials, Cancer Biomarkers, Gene Expression and Profiling REVIEW ARTICLES Source Type: research